Staff and Graduate Researchers
- Dr David Williams, BSc, GDipResMeth, PhD, Head
- A/Prof Christine E. Wright, BSc Hons, PhD
- Dr Kenneth D Winkel, MBBS, BMedSc, PhD, FACTM, Research fellow
- Dr Ronelle Welton, BBioMedSc Hons, PhD, MPHTM, Research Fellow
- Ms Dalia Ponce Garcia, BSc, MSc (UNAM, Mexico), PhD candidate
Australia has an international reputation for being the epicentre of all things venomous, whether it happens to be venomous snakes and arthropods on land, bees and wasps in the air, or lethal jellyfish, stingrays, stonefish and octopi in our oceans. The Australian Venom Research Unit (AVRU) conducts research with two main focus areas. The first is to characterise venoms and toxins in order to better understand the mechanism of envenomation and apply this understanding to improve treatment outcomes. A novel activity identified through this work has the potential for use as an investigational tool to aid in medical research and may identify drug discovery leads. The second is the use of public health applications to translate research and knowledge within a public forum and in addition quantify the burden of injury through epidemiological works.
To donate to the Unit please contact Ms Belinda Collins, Senior Development Manager for the Faculty of Medicine, Dentistry and Health Sciences.
- E: firstname.lastname@example.org
- P: +61 3 9035 3644
- A: Level 4, 766 Elizabeth Street, The University of Melbourne, Victoria 3010, Australia
Like to know more about how AVRU is saving lives?
- AVRU PNG brochure: AVRU in PNG (PDF, 2268.16 KB)
- Dr David Williams, AVRU on 30 Aug 2015: Radio interview on RRR Einstein A Go Go: "Antivenom work in PNG" with Dr David Williams
- AVRU on 29 Aug 2015 was discussed within the Harold Mitchell column urging philanthropic donation to the AVRU project in Papua New Guinea
- Dr David Williams, AVRU on 17 Jul 2015 was filmed in Papua New guinea and this aired as an AlJazeera documentary: Papua New Guinea Snake man
- Dr David Williams, AVRU on 8 Aug 2015 was interviewed by The Voice "One Shot Vial to help Villagers" and discusses the AVRU project in Papua New Guinea
- See also the face book page for the PNG project through the Charles Campbell Toxinology Center Facebook page
AVRU advisory board
- Professor Emeritus James Angus AO, Pharmacology and Therapeutics, University of Melbourne (Chair)
- Professor Danny Liew, Director of Melbourne EpiCentre
- Professor Shaun Ewen, Melbourne Poche Centre for Indigenous Health, University of Melbourne
- A/Prof James Tibballs, Royal Children's Hospital, Melbourne
- Dr John Bates, Honorary and former Business Development Manger within University of Melbourne Commercial
Principal Honorary Fellows
- A/Prof James Tibballs, Royal Children's Hospital
- Prof P. Gopalakrishnakone, National University of Singapore
- Prof David Warrell, University of Oxford, UK
- Dr Simon Jensen, Nambour Hospital, Qld
- Dr Bill Nimorakiotakis, Epworth and Western Hospitals
- Dr Mark O'Shea, National Institute for Research into Aquatic Habitats, UK
- Dr Wolfgang Wüster, University of Wales, Bangor, UK
- Dr Nadine Levick, Miamonades Medical Center, NYC, USA
- Dr Katia Barbaro, Institute Butantan, SP, Brazil
- Dr Chris Barnes, Bundaberg Base Hospital
- Prof Teatulohi Matainaho, PNG Chief Scientist
- Prof José María Gutiérrez, Instituto Clodomiro Picado, Costa Rica
- Prof Juan Calvete, Instituto de Biomedicina de Valencia, Spain
- Mr Owen Paiva, Charles Campbell Toxinology Centre, University of PNG
- Dr Robin Oge, Port Moresby General Hospital
- A/Prof James Harrison, Flinders University
- A/Prof Peter Fenner, James Cook University
- Dr Angel Yanagihara, University of Hawaii
- Dr Diane Brinkman, Australian Institute of Marine Science
- Dr Jason Mulvenna, QIMR Berghofer Medical Research Institute
- Sharyl Crossley, Senior Aquarist, Tennessee Aquarium
- NH&MRC: A randomized, double-blinded controlled trial (RCT) of a new whole IgG, equine antivenom compared to the currently used F(ab')2 CSL taipan antivenom, for the treatment of Papuan taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea [2012–2014]
- Direct Australian Government NH&MRC: Research translation, engagement and injury surveillance [2013–2017]
- The Struan Sutherland Trust
- Miscellaneous small grants
A randomized, double-blinded controlled trial (RCT) of a new whole IgG, equine antivenom compared to the currently used F(ab')2 CSL taipan antivenom, for the treatment of Papuan taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea
As part of its research activity, AVRU investigates the clinical presentation and management of venomous bites and stings. This work is focused on snakebite in Australia and the Asia-Pacific. It also aims to enhance the evidence base underlying contemporary recommendations in the prevention and treatment of venomous bite and sting injuries through direct clinical research. Our key project, funded by an NH&MRC Project grant, is a clinical trial of a new whole IgG equine Papuan taipan antivenom that is taking place at Port Moresby General Hospital in Papua New Guinea (PNG). This new antivenom has been developed in collaboration with colleagues from the Instituto Clodomiro Picado (Costa Rica) and the University of PNG, and is the first new antivenom to be used for snakebite in humans in Australasia in more than 50 years. The development of this product has been driven by a desire to develop a template for the production of high potency, safe, effective and affordable antivenoms for deployment in developing nations, delivering a GMP-compliant product that meets rigorous WHO Standards at a price that is sustainable in the long term. In preclinical studies our new antivenom was found to have equivalent overall potency against Papuan taipan (Oxyuranus scutellatus) venom to the current antivenom product, and improved neutralisation of procoagulant toxins that cause bleeding. The clinical trial is currently in progress. Our success with this project has led to the establishment of purpose-built clinical snakebite research laboratory (The Charles Campbell Toxinology Centre) at the University of Papua New Guinea. In addition to recruiting patients to our clinical trial, our Snakebite Clinic at the Port Moresby General Hospital is responsible for the management of approximately 250 snakebite cases that present to the Emergency Department each year, and we have extended service delivery beyond the hospital by establishing the only free MICA-level ambulance retrieval service in PNG which enables us to send a medical team out to health centres within 150 km of Port Moresby to stabilise, treat and safely transport critically ill snakebite patients back to hospital.
The cardiovascular pharmacology of snake venoms from Papua New Guinea and Australia
Papua New Guinean snakes produce a wide range of toxins that affect different organ systems. Apart from the dominant clinical effects caused by neurotoxins and procoagulants, the venoms of some PNG snakes are also known to affect the cardiovascular system. Patients bitten by Papuan taipans (Oxyuranus scutellatus) may experience syncope or loss of consciousness very soon after being bitten, and those who survive and present at hospital show cardiac rhythm disturbances that are thought to be due to direct cardiotoxic effects. In addition, other threatening cardiovascular events such as extreme lowering or raising of heart rate or blood pressure have been observed after envenoming by some PNG snake species, underlining the cardiotoxic potential of PNG snake venoms. We are especially interested in the cardiovascular pharmacology of Papuan taipan and PNG small-eyed snake (Micropechis ikaheka) venoms, as well as Australian brown snake (Pseudonaja spp.) and taipan (Oxyuranus spp.) venom. In close collaboration with the Cardiovascular Therapeutics Unit, our research aims to elucidate the mechanism of cardiotoxicity using isolated cardiovascular tissues in vitro and in integrated preparations in vivo. The effectiveness of antivenoms raised against these species in Australia and Costa Rica will be compared against cardiovascular responses to particular snake venoms. In doing so, we are seeking further insights into the action of these venoms, providing avenues for novel drug discovery, as well as improvements in the treatment of envenomation.
Isolation and characterization of major venom proteins from Scyphozoan jellyfish using proteomic, transcriptomic and pharmacological approaches
Jellyfish venoms are rich sources of bioactive compounds, however few toxins have been completely isolated and characterized. Basic research investigating the proteomes of jellyfish venoms may lead to the discovery of promising compounds for the development of therapeutic agents or probes to study physiological pathways. The Scyphozoans, or 'true' jellyfish, have been somewhat neglected for toxin studies, compared to the more dangerous box jellyfish. Proteomic, transcriptomic and pharmacological studies are essential to identify and isolate toxic proteins/peptides as well as to elucidate their structures, mechanisms of action and molecular targets. In collaboration with the Cardiovascular Therapeutics Unit, the Tennessee Aquarium, the Australian Institute of Marine Sciences in Townsville and the Queensland Institute of Medical Research in Brisbane, we are working with venoms from the Atlantic sea nettle, Chrysaora quinquecirrha, and the Pacific sea nettle, Chrysaora fuscescens, in order to explore the proteomics and transcriptomics of each venom and characterise the pharmacological activities of crude venoms and isolated toxins using in vitro and in vivo bioassays.
The Australian Venomous Injury Project (AVIP), initiated in July 2014, has the goal to determine if there are significant and specific factors relevant to venomous injury by different types of organisms, environments, or specific individuals or groups of individuals that predispose them to poor outcomes. Australian national morbidity and mortality databases are developed in to geodatabases and are reviewed in order to note correlative associations to inform preclinical and public health research.
Medical History - Venom: Fear, Fascination and Discovery
From the first Dean of Medicine, the University of Melbourne has been part of the global debate on the nature of venom. Hence the AVRU builds on more than 150 years of venom research at the University. Material from diverse collections and archives of the University and associated institutions were combined to tell the story of the development and use of antivenom in Australia from colonial times until now. Visit the Medical History Museum, Venom: Fear, Fascination and Discovery.
- Gutiérrez JM, Burnouf T, Harrison RA, Calvete JJ, Brown NI, Jensen SD, Warrell DA, Williams DJ; Global Snakebite Initiative. A call for incorporating social research in the global struggle against snakebite. PLoS NTD. 2015: In press.
- Godinho S, Woolley M, Webb, JC, Winkel KD. Sharing Place, Learning Together: Perspectives and reflections on an educational partnership formation with a remote Indigenous community school. Aust J Indigenous Education 2015; 1 – 15 DOI: 10.1017/jie.2015.11.
- Godinho S, Woolley M, Webb, JC, Winkel KD. Sharing Place, Learning Together: A Two-Way Pedagogy. UNESCO Observatory E-Journal 2015; 4:2: 1-27.
- Paiva OK, Pla D, Wright CE, Beutler M, Sanz L, Gutiérrez JM, Williams DJ, Calvete JJ.
Combined venom gland cDNA sequencing and venomics of the New Guinea small-eyed snake, Micropechis ikaheka. J Proteomics 2014; 110: 209-229.
- Pla D, Paiva OK, Sanz L, Wright CE, Beutler M, Calvete JJ, Williams DJ, Gutiérrez JM.
Preclinical efficacy of Australian antivenoms against the venom of the small-eyed snake, Micropechis ikaheka, from Papua New Guinea: an antivenomics and neutralization study. J Proteomics 2014; 110: 198-208.
- Herrera M, Paiva OK, Pagotto AH, Segura A, Serrano SMT, Vargas M, Villalta M, Jensen SD, León G, Williams DJ, Gutiérrez JM.
Antivenomic characterization of two antivenoms against the venom of the taipan, Oxyuranus scutellatus, from Papua New Guinea and Australia. Am. J. Trop. Med. Hyg 2014; 91: 887-894.
- Gutiérrez JM, Burnouf T, Harrison RA, Calvete JJ, Kuch U, Warrell DA, Williams DJ for the Global Snakebite Initiative.
A multicomponent strategy to improve the availability of antivenom for treating snakebite envenoming. Bull World Health Organ 2014; 92: 532-536.
- Luna-Ramírez K, Bartok A, Restano-Cassulini R, Quintero-Hernández V, Coronas FIV, Christensen J, Wright CE, Panyi G, Possani LD.
Structure, molecular modeling and function of a novel potassium channel blocker, urotoxin, isolated from the venom of the Australian scorpion Urodacus yaschenkoi. Mol Pharmacol 2014; 86: 28-41.
- Atakuziev BU, Wright CE, Graudins A, Nicholson GM & Winkel KD.
Efficacy of Australian red-back spider (Latrodectus hasselti) antivenom in the treatment of clinical envenomation by the cupboard spider Steatoda capensis (Theridiidae). Toxicon 2014; 86: 68-78.
- Luna-Ramírez K, Sani MA, Silva-Sanchez J, Jiménez-Vargase JM, Reyna-Flores F, Winkel KD, Wright CE, Possani LD, Separovic F.
Membrane interactions and biological activity of antimicrobial peptides from Australian scorpion. Biochim Biophys Acta 2014; 1838: 2140-2148.
- Luna-Ramírez K, Quintero-Hernández V, Vargas-Jaimes L, Batista CV, Winkel KD, Possani LD.
Characterization of the venom from the Australian scorpion Urodacus yaschenkoi: molecular mass analysis of components, cDNA sequences and peptides with antimicrobial activity.
Toxicon 2013; 63: 44-54.
- Gutiérrez JM, Warrell DA, Williams DJ, Jensen S, Brown N, Calvete JJ, Harrison RA.
The need for full integration of snakebite envenoming within a global strategy to combat the neglected tropical diseases: the way forward. PLoS Negl Trop Dis 2013; 7: e2162.
- Warrell DA, Gutiérrez JM, Calvete JJ, Williams D.
New approaches & technologies of venomics to meet the challenge of human envenoming by snakebites in India. Indian J Med Res 2013; 138: 38-59.
- Webb JC, Godinho SC, Woolley MF, Winkel KD.
Sharing Place, Learning Together: the birthplace of new ways? Med J Aust 2013; 199: 69-71.
- Healy J, Winkel KD (Eds)
Venom; Fear, Fascination and Discovery, Exhibition Catalogue, Medical History Museum. University of Melbourne, 2013, ISBN 978 0 7340 4834 9.
- Hughes RJA, Angus JA, Winkel KD, Wright CE.
A pharmacological investigation of the venom extract of the Australian box jellyfish, Chironex fleckeri, in cardiac and vascular tissues.
Toxicol Lett 2012; 209: 11-20.
- Herrera M, Fernández J, Vargas M, Villalta M, Segura A, León G, Angulo Y, Paiva O, Matainaho T, Jensen SD, Winkel KD, Calvete JJ, Williams DJ, Gutiérrez JM.
Comparative proteomic analysis of the venom of the taipan snake, Oxyuranus scutellatus, from Papua New Guinea and Australia: Role of neurotoxic and procoagulant effects in venom toxicity.
J Proteomics 2012; 75: 2128-2140.
- Vargas M, Segura A, Herrera M, Villalta M, Estrada R, Cerdas M, Paiva O, Matainaho T, Jensen SD, Winkel KD, León G, Gutiérrez JM, Williams DJ.
Preclinical evaluation of caprylic acid-fractionated IgG antivenom for the treatment of Taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea.
PLoS Negl Trop Dis 2011; 5: e1144.
- Williams DJ, Brown N, Calvete J, Casewell N, Gutiérrez JM, Harrison R, Jensen SJ, Paiva O, Ratanabanangkoon K, Winkel KD, Wüster W, Warrell DA.
Ending the drought: new strategies for improving the flow of affordable, effective antivenoms in Asia and Africa.
J Proteomics 2011; 74: 1735-1767.
- Li R, Wright CE, Winkel KD, Gershwin LA, Angus JA.
The pharmacology of Malo maxima jellyfish venom extract in isolated cardiovascular tissues: a probable cause of the Irukandji syndrome in Western Australia. Toxicol Lett 2011; 201: 221-229.
- Lippmann JM, Fenner PJ, Winkel K, Gershwin LA.
Fatal and severe box jellyfish stings, including Irukandji stings, in Malaysia, 2000-2010.
J Travel Med 2011; 18: 275-281.
- Gutiérrez JM, Williams DJ, Fan HW, Warrell DA.
Snakebite envenoming from a global perspective: Towards an integrated approach.
Toxicon 2010; 56: 1223-1235.
- Williams DJ, Gutiérrez JM, Harrison R, Warrell DA, White J, Winkel KD, Gopalakrishnakone P.
An antidote for snake bite: The Global Snake Bite Initiative.
Lancet 2010; 375: 89-91.